MiniMax Chief Executive Yan Junjie at the company's Hong Kong listing ceremony. (Tommy Wang/AFP/Getty Images) Shares of Chinese artificial-intelligence startup MiniMax Group more than doubled in their ...

MiniMax shares doubled in Hong Kong debut, beating rival Zhipu AI’s first-day gains. The IPO highlights China’s race to fund homegrown AI firms despite U.S. curbs on advanced chips. Rapid user growth ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

Shanghai-based AI company MiniMax listed on the Hong Kong Stock Exchange on Jan. 9. Shares surged more than 50% during intraday trading, pushing the company’s market capitalization above HK$76.3 ...

Chinese artificial intelligence startup MiniMax Group Ltd. went public in Hong Kong today and raised about $619 million, highlighting strong investor appetite for generative AI companies on both sides ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

MiniMax Unveils M2.1 to Bring Multilingual Programming Gains to Open AI Models Your email has been sent Chinese AI startup’s release is a major update to its open-source model series, aimed at ...

What if the next big leap in AI wasn’t locked behind corporate paywalls but was instead freely available for anyone to explore, adapt, and innovate with? That’s exactly the promise of MiniMax M2.1, ...

Chinese artificial intelligence startup MiniMax today announced the release of M2.1, a significantly enhanced performance for real-world complex tasks and agentic capabilities across more programming ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...